Rett Syndrome — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for rett syndrome. 32 active patents protecting 1 drugs from 1+ originators. First major cliff: 2032. Daily refresh.

1
Approved drugs
32
Active US patents
62/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Rett Syndrome

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Acadia Pharms Inc 32 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating rett syndrome. Each bar = one year. Y-axis scaled to peak year (8 patents).

8
32
4
40
4
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Daybue
TROFINETIDE
 Acadia Pharms Inc 32 62 $300M 2032-01-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9212204 Daybue method of use 81 2032-01-27
9212204 Daybue method of use 81 2032-01-27
9212204 Daybue method of use 81 2032-01-27
9212204 Daybue method of use 76 2032-01-27
11827600 Daybue method of use 75 2042-07-12
12492167 Daybue method of use 75 2042-07-12
12492167 Daybue method of use 75 2042-07-12
12492167 Daybue method of use 75 2042-07-12
11827600 Daybue method of use 75 2042-07-12
11827600 Daybue method of use 75 2042-07-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11370755 Daybue composition of matter 12 2040-08-03
11370755 Daybue composition of matter 17 2040-08-03
11370755 Daybue composition of matter 17 2040-08-03
11370755 Daybue composition of matter 17 2040-08-03
12492167 Daybue other 62 2043-01-12
11827600 Daybue other 62 2043-01-12
12492167 Daybue other 62 2043-01-12
12492167 Daybue other 62 2043-01-12
11827600 Daybue other 62 2043-01-12
12492167 Daybue other 62 2043-01-12

Related